Literature DB >> 33620997

Luts-V: A new simplified score for assessing lower urinary tract symptoms in men.

Caroline Santos Silva1, Ueslei Menezes de Araujo2, Mateus Andrade Alvaia2, Kátia Santana Freitas1, Taciana Leonel Nunes Tiraboschi1, Cristiano Mendes Gomes3, José de Bessa1,4.   

Abstract

OBJECTIVES: Develop and validate a new and simplified score for evaluating the lower urinary tract symptoms in men.
MATERIALS AND METHODS: We modified the existing visual prostate symptom score, including changes in the images, sequence, and new alternatives, resulting in a new visual score (LUTS visual score-LUTS-V). For the validation of the new tool, we used the International Prostatic Symptom Score as the gold-standard and the new LUTS-V to 306 men. The total IPSS score and the total LUTS-V score of each subject were evaluated to determine the agreement between the two instruments. ROC curve was used to evaluate the diagnostic accuracy and best cut-off of LUTS-V. Sensitivity, specificity, and diagnostic odds ratios were used to describe the diagnostic properties.
RESULTS: The mean age of the participants was 59 [52-87] years. There was a significant correlation between LUTS-V and IPSS. (r=0.72 (p<0.0001). The Bland-Altman analyzes demonstrate good agreement between the two questionnaires (bias=5.6%). LUTS-V demonstrated excellent diagnostic accuracy in detecting the most serious cases with an area under the ROC curve of 83% [78-87%] 95% CI. p <0.001). LUTS-V >4 was the best threshold, with a sensitivity of 74% and specificity of 78%.
CONCLUSIONS: LUTS-V is a simple, self-administered tool with a significant discriminatory power to identify subjects with moderate to severe LUTS and may represent a useful instrument for the diagnosis and follow-up of men with urinary symptoms. Copyright® by the International Brazilian Journal of Urology.

Entities:  

Keywords:  Men; Prostate; Validation Study [Publication Type]

Year:  2021        PMID: 33620997      PMCID: PMC7993949          DOI: 10.1590/S1677-5538.IBJU.2020.0278

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  24 in total

1.  The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes.

Authors:  Lidwine B Mokkink; Caroline B Terwee; Donald L Patrick; Jordi Alonso; Paul W Stratford; Dirk L Knol; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2010-07       Impact factor: 6.437

Review 2.  Patient-reported outcome measures in urology.

Authors:  Gopal L Narang; Stephanie C Pannell; Aaron A Laviana; Kathy H Y Huen; Jason Izard; Angela B Smith; Jonathan Bergman
Journal:  Curr Opin Urol       Date:  2017-07       Impact factor: 2.309

3.  One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.

Authors:  B Lukacs; J C Grange; D Comet
Journal:  Urology       Date:  2000-04       Impact factor: 2.649

4.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

5.  The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).

Authors:  Aurélien Descazeaud; Patrick Coloby; Alexandre De La Taille; Gilles Karsenty; Georges Kouri; Dominique Rossi; Fréderic Carrois; Marc Zerbib
Journal:  Presse Med       Date:  2018-07-31       Impact factor: 1.228

6.  Assessment of the performance of the American Urological Association symptom score in 2 distinct patient populations.

Authors:  Timothy V Johnson; Evan D Schoenberg; Ammara Abbasi; Samantha S Ehrlich; Renee Kleris; Ashli Owen-Smith; Kristin Gunderson; Viraj A Master
Journal:  J Urol       Date:  2008-11-14       Impact factor: 7.450

7.  Comprehension and construct validity of the Visual Prostate Symptom Score (VPSS) by men with obstructive lower urinary tract symptoms in rural Africa.

Authors:  Lynn Stothers; Andrew Macnab; Francis Bajunirwe; Sharif Mutabazi; Catherine Lobatt
Journal:  Can Urol Assoc J       Date:  2017-11       Impact factor: 1.862

8.  The prevalence of lower urinary tract symptoms (LUTS) in Brazil: Results from the epidemiology of LUTS (Brazil LUTS) study.

Authors:  Roberto Soler; Cristiano Mendes Gomes; Marcio Augusto Averbeck; Mitti Koyama
Journal:  Neurourol Urodyn       Date:  2017-11-06       Impact factor: 2.696

9.  The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis.

Authors:  Shaun Wen Huey Lee; Esther Mei Ching Chan; Yin Key Lai
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

10.  Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia.

Authors:  Teddy Kajimotu; Kasonde Bowa
Journal:  PLoS One       Date:  2018-06-26       Impact factor: 3.240

View more
  2 in total

1.  How Do Patients Understand Questions about Lower Urinary Tract Symptoms? A Qualitative Study of Problems in Completing Urological Questionnaires.

Authors:  Florine W M Schlatmann; Michael R van Balken; Andrea F de Winter; Igle-Jan de Jong; Carel J M Jansen
Journal:  Int J Environ Res Public Health       Date:  2022-08-05       Impact factor: 4.614

2.  Editorial Comment: Luts-V: A new simplified score for assessing lower urinary tract symptoms in men.

Authors:  Ralf Anding
Journal:  Int Braz J Urol       Date:  2021 May-Jun       Impact factor: 1.541

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.